Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 7
2005 6
2006 10
2007 7
2008 8
2009 10
2010 4
2011 7
2012 6
2013 7
2014 10
2015 8
2016 18
2017 18
2018 14
2019 12
2020 23
2021 32
2022 26
2023 38
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Results by year

Filters applied: . Clear all
Page 1
Classification of psychodermatological disorders: Proposal of a new international classification.
Ferreira BR, Vulink N, Mostaghimi L, Jafferany M, Balieva F, Gieler U, Poot F, Reich A, Romanov D, Szepietowski JC, Tomas-Aragones L, Campos R, Tausk F, Zipser M, Bewley A, Misery L. Ferreira BR, et al. Among authors: reich a. J Eur Acad Dermatol Venereol. 2024 Apr;38(4):645-656. doi: 10.1111/jdv.19731. Epub 2023 Dec 12. J Eur Acad Dermatol Venereol. 2024. PMID: 38084889
Validation of the Wound-QoL-17 and the Wound-QoL-14 in a European sample of 305 patients with chronic wounds.
Janke TM, Kozon V, Valiukeviciene S, Rackauskaite L, Reich A, Stępień K, Chernyshov P, Jankechová M, van Montfrans C, Amesz S, Barysch M, Montero EC, Augustin M, Blome C. Janke TM, et al. Among authors: reich a. Int Wound J. 2023 Dec 4;21(3):e14505. doi: 10.1111/iwj.14505. Online ahead of print. Int Wound J. 2023. PMID: 38049311 Free PMC article.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
Papp KA, Lebwohl MG, Thaçi D, Jaworski J, Kwiek B, Trefler J, Dudek A, Szepietowski JC, Reznichenko N, Narbutt J, Baran W, Kolinek J, Daniluk S, Bartnicka-Maslowska K, Reich A, Andrashko Y, Kim S, Bae Y, Jeon D, Jung J, Lee H, Pyo T, Ko W. Papp KA, et al. Among authors: reich a. BioDrugs. 2024 Jan;38(1):121-131. doi: 10.1007/s40259-023-00630-5. Epub 2023 Nov 22. BioDrugs. 2024. PMID: 37991693 Free PMC article. Clinical Trial.
256 results